NRX Pharmaceuticals IncNASDAQ:NRXPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3100
- TODAY'S CHANGE (%)0.0500 (3.9683%)
- Bid / Lots1.3100/ 2
- Ask / Lots1.3200/ 1
- Open / Previous Close1.2600 / 1.2600
- Day Range
- 52 Week Range
- Volume610,284
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXP |
|---|---|---|
| 09:32 ET | 4155 | 1.27 |
| 09:33 ET | 6400 | 1.3 |
| 09:35 ET | 1300 | 1.3 |
| 09:39 ET | 8251 | 1.31 |
| 09:42 ET | 5411 | 1.32 |
| 09:48 ET | 160 | 1.325 |
| 09:50 ET | 203 | 1.325 |
| 09:51 ET | 400 | 1.32 |
| 09:53 ET | 125 | 1.3168 |
| 09:55 ET | 1450 | 1.33 |
| 10:02 ET | 500 | 1.32 |
| 10:04 ET | 750 | 1.31 |
| 10:06 ET | 1711 | 1.325 |
| 10:08 ET | 1339 | 1.33 |
| 10:09 ET | 36323 | 1.35 |
| 10:11 ET | 1306 | 1.34 |
| 10:13 ET | 1700 | 1.36 |
| 10:15 ET | 8325 | 1.32 |
| 10:18 ET | 12945 | 1.33 |
| 10:20 ET | 3697 | 1.34 |
| 10:22 ET | 600 | 1.33 |
| 10:24 ET | 7300 | 1.33 |
| 10:27 ET | 1543 | 1.33 |
| 10:29 ET | 26852 | 1.31 |
| 10:31 ET | 5090 | 1.33 |
| 10:33 ET | 300 | 1.32 |
| 10:38 ET | 16592 | 1.3 |
| 10:40 ET | 400 | 1.3 |
| 10:42 ET | 1288 | 1.3 |
| 10:44 ET | 900 | 1.315 |
| 10:45 ET | 430 | 1.3 |
| 10:47 ET | 7835 | 1.315 |
| 10:58 ET | 3060 | 1.325 |
| 11:00 ET | 2000 | 1.32 |
| 11:02 ET | 2119 | 1.32 |
| 11:07 ET | 1310 | 1.33 |
| 11:09 ET | 295 | 1.32 |
| 11:12 ET | 100 | 1.31 |
| 11:14 ET | 122 | 1.32 |
| 11:18 ET | 2100 | 1.3202 |
| 11:21 ET | 700 | 1.32 |
| 11:23 ET | 6754 | 1.3 |
| 11:30 ET | 2500 | 1.3 |
| 11:32 ET | 12554 | 1.31 |
| 11:34 ET | 100 | 1.3 |
| 11:36 ET | 3500 | 1.34 |
| 11:38 ET | 13162 | 1.35 |
| 11:45 ET | 200 | 1.36 |
| 11:48 ET | 270 | 1.35 |
| 11:57 ET | 400 | 1.36 |
| 11:59 ET | 34082 | 1.43 |
| 12:01 ET | 20870 | 1.4297 |
| 12:03 ET | 3290 | 1.43 |
| 12:06 ET | 27814 | 1.4501 |
| 12:08 ET | 5097 | 1.47 |
| 12:10 ET | 4366 | 1.47 |
| 12:12 ET | 9348 | 1.4619 |
| 12:14 ET | 8439 | 1.4495 |
| 12:15 ET | 21000 | 1.45 |
| 12:17 ET | 7209 | 1.45 |
| 12:19 ET | 6356 | 1.4477 |
| 12:21 ET | 2654 | 1.451 |
| 12:24 ET | 500 | 1.4591 |
| 12:26 ET | 600 | 1.45 |
| 12:30 ET | 450 | 1.46 |
| 12:32 ET | 2300 | 1.46 |
| 12:35 ET | 100 | 1.465 |
| 12:42 ET | 578 | 1.4675 |
| 12:44 ET | 100 | 1.465 |
| 12:48 ET | 40847 | 1.43 |
| 12:50 ET | 6072 | 1.38 |
| 12:51 ET | 1500 | 1.36 |
| 12:53 ET | 5400 | 1.38 |
| 12:55 ET | 200 | 1.39 |
| 12:57 ET | 2730 | 1.382 |
| 01:00 ET | 100 | 1.38 |
| 01:02 ET | 100 | 1.395 |
| 01:04 ET | 300 | 1.4049 |
| 01:08 ET | 419 | 1.4 |
| 01:09 ET | 2125 | 1.41 |
| 01:11 ET | 1400 | 1.41 |
| 01:13 ET | 3200 | 1.38 |
| 01:15 ET | 4400 | 1.36 |
| 01:18 ET | 3600 | 1.385 |
| 01:20 ET | 500 | 1.39 |
| 01:22 ET | 1000 | 1.38 |
| 01:24 ET | 1200 | 1.37 |
| 01:26 ET | 200 | 1.37 |
| 01:27 ET | 7478 | 1.365 |
| 01:29 ET | 23086 | 1.32 |
| 01:31 ET | 400 | 1.34 |
| 01:38 ET | 905 | 1.34 |
| 01:42 ET | 3100 | 1.35 |
| 01:44 ET | 100 | 1.35 |
| 01:45 ET | 6356 | 1.355 |
| 01:47 ET | 1800 | 1.34 |
| 01:49 ET | 9490 | 1.3301 |
| 01:51 ET | 100 | 1.34 |
| 01:54 ET | 2200 | 1.33 |
| 01:56 ET | 10056 | 1.3199 |
| 01:58 ET | 2500 | 1.3129 |
| 02:02 ET | 500 | 1.33 |
| 02:03 ET | 339 | 1.33 |
| 02:05 ET | 3200 | 1.33 |
| 02:07 ET | 500 | 1.33 |
| 02:09 ET | 3000 | 1.3249 |
| 02:12 ET | 4080 | 1.321 |
| 02:14 ET | 10000 | 1.33 |
| 02:16 ET | 11707 | 1.33 |
| 02:18 ET | 5000 | 1.33 |
| 02:20 ET | 3986 | 1.32 |
| 02:21 ET | 800 | 1.325 |
| 02:23 ET | 8356 | 1.305 |
| 02:25 ET | 500 | 1.31 |
| 02:27 ET | 5000 | 1.325 |
| 02:34 ET | 300 | 1.33 |
| 02:36 ET | 100 | 1.33 |
| 02:38 ET | 200 | 1.33 |
| 02:39 ET | 900 | 1.33 |
| 02:41 ET | 400 | 1.33 |
| 02:43 ET | 2200 | 1.32 |
| 02:45 ET | 4900 | 1.3 |
| 02:48 ET | 600 | 1.31 |
Today
DJ NRX Pharmaceuticals Price Target Maintained With a $19.00/Share by HC Wainwright & Co., from 6 hours ago by Dow Jones
6 hours ago by Dow JonesNRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials", from 7 hours ago by Dow Jones
7 hours ago by Dow Jones
Nov 18, 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer, from 4:05PM ET on Monday Nov 18, 2024 by Dow Jones
4:05PM ET on Monday Nov 18, 2024 by Dow Jones*DJ NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams As Chief Financial Officer >NRXP, from 4:05PM ET on Monday Nov 18, 2024 by Dow Jones
4:05PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
DJ NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital, from 5:09PM ET on Friday Nov 15, 2024 by Dow Jones
5:09PM ET on Friday Nov 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NRX Pharmaceuticals Inc | 13.5M | -0.8x | --- |
Sensei Biotherapeutics Inc | 13.1M | -0.5x | --- |
PharmaCyte Biotech Inc | 13.1M | 3.5x | --- |
HST Global Inc | 12.8M | -14.8x | --- |
Inhibitor Therapeutics Inc | 12.8M | -4.2x | --- |
NKGen Biotech Inc | 12.6M | -0.1x | --- |
Company Information
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Contact Information
- Headquarters
- 1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801
- Phone
- 484-254-6134
- Fax
- 302-575-1642
Executives
- Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
- Jonathan Javitt
- Chief Financial Officer
- Michael Abrams
- CMC and Technical Operations Advisor
- Riccardo Panicucci
- Independent Director
- Patrick Flynn
- Independent Director
- Sharon Glied
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.69 |
Book Value | $-0.14 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
